Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
retirement
The top shares of Australia’s best performing super funds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,561.80 | 49.90 | -0.58% |
| CAC 40 | 7,910.49 | 31.93 | -0.40% |
| DAX 40 | 24,122.40 | 86.29 | 0.36% |
| Dow JONES (US) | 41,860.44 | 816.80 | -1.91% |
| FTSE 100 | 8,786.46 | 5.34 | 0.06% |
| HKSE | 23,695.88 | 131.90 | -0.55% |
| NASDAQ | 18,872.64 | 270.07 | -1.41% |
| Nikkei 225 | 36,914.18 | 384.80 | -1.03% |
| NZX 50 Index | 12,650.24 | 52.86 | -0.42% |
| S&P 500 | 5,844.61 | 95.85 | -1.61% |
| S&P/ASX 200 | 8,340.90 | 45.90 | -0.55% |
| SSE Composite Index | 3,387.63 | 0.05 | 0.00% |